Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

Income, Education May Affect How Patients View Their Capabilities

Among people with systemic scleroderma, education and income are major determinants of perceived functional ability, a new study indicates. Findings also point to skin involvement and age as substantial determinants of functionality. “These results may serve to give clinicians novel insight into the predictive factors of patient function and…

Phase 2 Trial of PRA023 in SSc-ILD Patients Planned for Next Year

Prometheus Biosciences is planning a clinical trial of its investigational anti-inflammatory and antifibrotic medication PRA023 in people with systemic scleroderma-associated interstitial lung disease (SSc-ILD), a form of scleroderma characterized by inflammation and scarring (fibrosis) in the lungs. The Phase 2 study, called ATHENA-SSc-ILD, is planned to launch early…

Scleroderma Renal Crisis More Common in Blacks, Study Finds

Scleroderma renal crisis (SRC), a rare and severe manifestation of systemic scleroderma, is disproportionately common in Blacks, a new study reports. “Black race was independently associated with a higher risk of future SRC,” its researchers wrote. “Further studies are needed to elucidate the mechanisms that underlie this important association.”…

Surveyed Patients Report Satisfaction With Treatment

Most scleroderma patients who responded to a U.S.-based online survey report being satisfied with their current medications and are not considering switching treatments. However, only about half of survey respondents reported being satisfied with their overall life quality, or optimistic about the future, perhaps highlighting gaps in care for…

Trial of COVID-19 Booster Vaccine Opens in Autoimmune Diseases

An enrolling clinical trial is assessing whether a “booster shot” of a COVID-19 vaccine can improve the immune response in people with scleroderma and other autoimmune diseases who did not respond, at all or optimally, to their original COVID-19 vaccine regimen. The study also will test whether temporarily stopping…